Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).
Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigator’s choice of chemotherapy in patients with endometrial cancer after receipt of platinum-based chemotherapy and PD-L1 inhibition (Abstract TPS5646).
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have been pretreated with Bruton tyrosine kinase covalent inhibitors (Abstract TPS7100).
For more information about the trial, visit ClinicalTrials.gov (identifier NCT07342478).
Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibitor durvalumab in patients with extensive-stage small cell lung cancer (SCLC) (Abstract LBA8005).
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-04 trial. The study compared sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1–positive metastatic triple-negative breast cancer (Abstract LBA1000).
Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515).
